Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 3/20 | 0.41 |
| ▸ | BECN1 | Q14457 | 3/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014282 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL29140311 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL28983970 | 0.76 | KDM4E (0.46) | SMN1; SMN2NPC1RAB9AHTTKMT2A | |
| SCHEMBL1258860 | 0.76 | HPGD (0.50) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL7079634 | 0.75 | RAB9A (0.64) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL28793821 | 0.75 | RAB9A (0.62) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL12191262 | 0.74 | — | — | |
| SCHEMBL11145023 | 0.73 | CTSS (0.49) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL9547521 | 0.73 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL27803426 | 0.72 | CA1 (0.42) | SMN1; SMN2MAPTHTTCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | claimed |
| WO-2024069634-A1 | MICROTUBULE TARGETING AGENTS | Ariel Scientific Innovations Ltd. (IL) | 2024-04-04 | — | — | WO | disclosed |
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20200032143-A1 | COMPOUND HAVING DIBENZOFURAN RING, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2020-01-30 | — | — | US | disclosed |
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2019-10-01 | — | — | US | disclosed |
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3315583-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | CELGENE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| WO-2007136640-A2 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE | CELGENE CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7247355-B2 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247355-B2 | Liquid crystal compound having chroman ring, liquid crystal composition comprising the compound and liquid crystal display device comprising the composition | CHISSO CORPORATION (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1465896-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050032817-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
| EP-1465896-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003050122-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | SMN1; SMN2 3837/4885NPC1 1740/4885RAB9A 2259/4885 |
| US-20050032817-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung | KIF2C, KIFC1, KIF5B | SMN1; SMN2 2534/4885NPC1 2521/4885RAB9A 2293/4885 |
| US-20080064876-A1 | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | TNF, DHPS, IDO1 | SMN1; SMN2 2108/4885NPC1 3122/4885RAB9A 3356/4885 |
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | PIEZO1, PYCARD, NLRP1 | SMN1; SMN2 4012/4885NPC1 2810/4885RAB9A 2454/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | SMN1; SMN2 3837/4885NPC1 1740/4885RAB9A 2259/4885 |
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | SMN1; SMN2 4282/4885NPC1 2198/4885RAB9A 2387/4885 |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, NLRP1, PYCARD | SMN1; SMN2 4017/4885NPC1 2871/4885RAB9A 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.